Premium
Failure of Platelet Markers to Evaluate Membrane Biocompatibility During a Combined Hemodialysis‐Hemoperfusion Treatment
Author(s) -
Buccianti G.,
Giaretto S.,
Pogliani E. M.,
Lorenz M.,
Valenti G.,
Bianchi M. L.,
Cresseri D.
Publication year - 1987
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1987.tb00954.x
Subject(s) - hemoperfusion , biocompatibility , hemodialysis , platelet , platelet activation , thrombogenicity , heparin , pharmacology , platelet factor 4 , thromboxane , ex vivo , in vivo , thromboxane b2 , chemistry , medicine , in vitro , immunology , biochemistry , biology , microbiology and biotechnology , organic chemistry
Plasma levels of the platelet markers β‐throm‐boglobulin (β‐TG) and platelet factor 4 (PF 4 ) are among the most sophisticated indexes of biocompatibility available to evaluate new members for hemodialysis. This investigation was designed to determine the extent of platelet activation by measuring the α‐granule release products, β‐TG and PF 4 ; anticoagulation and thrombo‐genesis by monitoring plasma heparin; and fibrinopeptide A (FPA) and thromboxane B 2 (TX B 2 ) levels during treatment with a combined hemodialysis‐hemoperfusion system. Both in vivo and in vitro results showed that the platelet markers had a pattern different from that generally observed during treatment with hemodialysis alone. This is due to the avidity of charcoal for the markers studied, which therefore cannot be used to evaluate the biocompatibility of the system.